Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females aged ≥18 years;~2. ECOG performance status (PS) 0-2;~3. Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not eligible);~4. Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;~5. Have adequate organ function;~6. Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.~Exclusion Criteria:~1. Secondary or familial amyloidosis;~2. Life expectancy of \< 3 months;~3. Symptomatic multiple myeloma;~4. Hypersensitivities to other monoclonal antibodies;~5. Known HIV infection;~6. Women who are lactating;~7. Any other condition or prior therapy, which in the opinion of the PI, would make the subject unsuitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NEOD001 (Type: EXPERIMENTAL): NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).